text: Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (<< N4-pentoxycarbonyl-5'-5-fluorocytidine >>) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of [[ thymidylate synthase ]] (TS).